3-Dimensional Mapping System: The PULSTAR Study

Inclusion Criteria: * ≥18 and ≤75 years of age. * Paroxysmal atrial fibrillation diagnosed by electrocardiogram or Holter ECG (including single-lead ECG recorder, lasting≥30s) within 1 year prior to enrollment. * Clinical diagnosis of paroxysmal atrial fibrillation. * Symptomatic patients who are ineffective or intolerant to at least one antiarrhythmic medication; or patients who are willing to undergo ablation despite not being on medication. * Fully understand the treatment protocol and voluntarily sign the informed consent form and be willing to undergo the tests, procedures and follow-ups required by the protocol. Exclusion Criteria: * Patients who have undergone left atrial surgery * Left atrial thrombosis * Patients of childbearing age who are unable to use effective contraception during the 12-month period after enrollment * Anterior and posterior left atrial diameter ≥ 50 mm * Left ventricular ejection fraction (LVEF) ≤ 40% * Previous atrial septal repair or atrial mucinous tumor * Active implants (e.g. pacemakers, ICDs, etc.) in the body * NYHA class III-IV cardiac function \[Appendix 1\] * Clear cerebrovascular disease within the last 6 months (including cerebral hemorrhage, stroke, transient ischemic attack) * Cardiovascular events within the last 3 months (including acute myocardial infarction, coronary intervention or heart bypass surgery, prosthetic valve replacement or repair, atrial or ventriculotomy) * Those with acute or severe systemic infections * Patients with severe liver or kidney disease, malignant tumors or end-stage disease that, in the opinion of the investigator, may interfere with the treatment, evaluation and compliance of this trial * Patients with significant bleeding tendency, hypercoagulable state and severe hematologic disorders * Patients who have participated or are participating in other clinical trials within 3 months prior to enrollment * Patients who have other conditions that the investigator considers inappropriate for participation in this trial.